Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis

Acta Oncologica

Volumn 48, Issue 1, 2009, Pages 9-17

  Zhu, Xiaolei ^a   Stergiopoulos, Kathleen ^b   Wu, Shenhong ^b,c  

^a Kidney Specialists of Long Island   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c Stony Brook Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IMATINIB; INTERFERON; PLACEBO; SUNITINIB;

CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STOMACH CANCER; SYSTEMATIC REVIEW; UROGENITAL TRACT CANCER;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPERTENSION; INDOLES; KIDNEY DISEASES; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 58149098429     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802314720     Document Type: Review

References (41)

1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
2. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
3. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004;7:225-33.
4. Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-66.
5. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-16.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 2007;356:115-24.
7. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
8. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
9. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-38.
10. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-9.
11. Pfizer. Sutent Prescribing Information, updated on 2/07, available at http:/www.pfizer.com/pfizer/download/uspi_sutent.pdf. 2006.
12. NCI, Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE). Available at http:/ctep.cancer.gov/reporting/ctc.html. 2006.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
14. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6.
15. Gore ME, Oudard S, Bjarnason G, Castellano D, Szczylik C, Mainwaring PN, et al. Sunitinib in Metastatic Renal Cell Carcinoma (mRCC): Preliminary assessment in an expanded access trial with subpopulation analysis. In: 43rd ASCO Annual Meeting; 2007 June 20, 2007; Chicago, IL; 2007. p. 237s.
16. Reichardt P, Ruka W, Seddon B, Baum CM, Demetri GD. Subpopulation analyses in a worldwide treatment-use trial of sunitinib (SU) in GIST patients (pts) with resistance or intolerance to prior imatinib (IM) therapy. In: 43rd ASCO Annual Meeting; 2007 June 20, 2007; Chicago, IL; 2007. p. 550s.
17. Bang Y, Kang W, Boku N, Chung H, Lanzalone S, Lechuga MJ, et al. Sunitinib as second-line treatment for advanced gastric cancer: Preliminary results from a Phase II study. In: 43rd ASCO Annual Meeting; 2007 June 20, 2007; Chicago, IL; 2007. p. 223s.
18. Brahmer JR, Novello S, Rosell R, Belani CP, Atkins JN, Gillenwater HH, et al. Efficay and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a Phase II study. In: 43rd ASCO Annual Meeting; 2007 June 20, 2007; Chicago, IL; 2007. p. 395s.
19. George S, Casali PG, LeCesne A, Morgan JA, Pokela J, Quigley MT, et al. Continuous daily dosing of sunitinib malate compares favorably with intermittent dosing in patients with advanced GIST. In: 43rd ASCO Annual Meeting; 2007 June 20, 2007; Chicago, IL; 2007. p. 548s.
20. Iasonos A, Riches J, Bajorin DF. Phase II study of sunitinib in patients with repalpsed or refractory urothelial carcinoma. In: 43rd ASCO Annual Meeting; 2007 June 20, 2007; Chicago, IL; 2007. p. 254s.
21. Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety of sunitinib Malate (SU11248, Sutent) in bevacizumab-refractory metastatic renal cell carcinoma. In: ASCO Annual meeting; 2006; Atlanta, GA; 2006. p. 222s, Abstract # 4522.
22. Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in previously treated advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. ASCO Annual Meeting Proceedings 2006;24: 364s, Abstract # 7001.
23. Srinivas S, Gillessen S, Hamenberg U, De Mulder PH, Fountzilas G, Vogelzang N, et al. Continuous daily administration of sunitinib in patients with cytokine-refractory mestatic renal cell carcinoma: Updated results. In: 43rd ASCO Annual Meeting; 2007 June 20, 2007; Chicago, IL; 2007. p. 244s.
24. Kaplan NM, Opie LH. Controversies in hypertension. Lancet 2006;367:168-76.
25. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Internal Med 1995;123:754-62.
26. Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007;18:1745-7.
27. Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007;25:3559.
28. Zhu X, Perazella MA. Anti-vascular endotehlial growth factor (VEGF) therapy: A new cause of hypertension. Hypertens Rev 2007;accepted.
29. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in cancer patients. Lancet Oncol 2008;(in press).
30. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-93.
31. Sica DA. Angiogenesis inhibitors and hypertension: An emerging issue. J Clin Oncol 2006;24:1329-31.
32. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2007.
33. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24:1363-9.
34. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Inter 1985;28:830-8.
35. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-16.
36. Bayer. NEXAVAR Prescribing Information, 8/06, available at http:/www.nexavar.com/wt/page/index. 2006.
37. Siddiqui AJ, Mansson-Broberg A, Gustafsson T, et al. Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart. Am J Hypertens 2005;18:1347-52.
38. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 2006;12:2888-93.
39. Miura S, Fujino M, Matsuo Y, Tanigawa H, Saku K. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res 2005;28:147-53.
40. Agabiti-Rosei E. Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy. Drugs 2003;63:19-29.
41. Mares JE, Worah S, Mathew SV, et al. Increased rates of hypertension (HTN) among patients with advanced carcinoid treated with bevacizumab. The 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) 2005: Abstract No: 4087